SG10201912275YA - Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders - Google Patents
Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disordersInfo
- Publication number
- SG10201912275YA SG10201912275YA SG10201912275YA SG10201912275YA SG10201912275YA SG 10201912275Y A SG10201912275Y A SG 10201912275YA SG 10201912275Y A SG10201912275Y A SG 10201912275YA SG 10201912275Y A SG10201912275Y A SG 10201912275YA SG 10201912275Y A SG10201912275Y A SG 10201912275YA
- Authority
- SG
- Singapore
- Prior art keywords
- pi3kd
- treatment
- related disorders
- pyrazolopyrimidine derivatives
- pyrazolopyrimidine
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771480P | 2013-03-01 | 2013-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912275YA true SG10201912275YA (en) | 2020-04-29 |
Family
ID=50288319
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201707130UA SG10201707130UA (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders |
| SG11201506654UA SG11201506654UA (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
| SG10201912275YA SG10201912275YA (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201707130UA SG10201707130UA (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders |
| SG11201506654UA SG11201506654UA (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US9932341B2 (de) |
| EP (3) | EP2961410B1 (de) |
| JP (4) | JP6545106B2 (de) |
| KR (4) | KR102454308B1 (de) |
| CN (2) | CN109010343A (de) |
| AR (1) | AR094964A1 (de) |
| AU (4) | AU2014223257B2 (de) |
| BR (1) | BR112015020941A2 (de) |
| CA (1) | CA2901993C (de) |
| CL (1) | CL2015002442A1 (de) |
| CR (1) | CR20150472A (de) |
| CY (1) | CY1122712T1 (de) |
| DK (1) | DK2961410T3 (de) |
| EA (2) | EA202192151A1 (de) |
| ES (2) | ES2774436T3 (de) |
| HK (1) | HK1221398A1 (de) |
| HR (1) | HRP20200263T1 (de) |
| HU (1) | HUE047719T2 (de) |
| IL (6) | IL311666A (de) |
| LT (1) | LT2961410T (de) |
| MX (2) | MX367713B (de) |
| MY (1) | MY177875A (de) |
| PE (1) | PE20151996A1 (de) |
| PH (2) | PH12015501920A1 (de) |
| PL (1) | PL2961410T3 (de) |
| PT (1) | PT2961410T (de) |
| RS (1) | RS59958B1 (de) |
| SG (3) | SG10201707130UA (de) |
| SI (1) | SI2961410T1 (de) |
| TW (5) | TW202214254A (de) |
| UA (1) | UA119641C2 (de) |
| WO (1) | WO2014134426A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845856A1 (de) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidone als PI3K-Hemmer |
| EP3513793B1 (de) | 2011-09-02 | 2021-03-10 | Incyte Holdings Corporation | Heterocyclylamine als pi3k-hemmer |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ES2790419T3 (es) | 2013-01-15 | 2020-10-27 | Incyte Holdings Corp | Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM |
| TW202214254A (zh) * | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| MX2016013182A (es) | 2014-04-08 | 2017-04-27 | Incyte Corp | Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k). |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| EP4086259A1 (de) | 2015-11-06 | 2022-11-09 | Incyte Corporation | Heterocyclische verbindungen als pi3k-gamma-hemmer |
| MA54567A (fr) | 2016-01-05 | 2021-10-27 | Incyte Corp | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma |
| KR102375929B1 (ko) | 2016-03-31 | 2022-03-16 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌린 유사체 및 이의 용도 |
| TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| MX2020002630A (es) * | 2017-09-08 | 2020-07-20 | Beigene Ltd | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. |
| IL295978B2 (en) | 2017-10-18 | 2024-01-01 | Incyte Corp | Concentrated imidazole derivatives substituted by tertiary hydroxy groups as P13K-gamma inhibitors |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| HRP20221449T1 (hr) * | 2018-01-10 | 2023-01-20 | Idorsia Pharmaceuticals Ltd | Derivati 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona i pripadajući spojevi kao modulatori c5a receptora za liječenje vaskulitisa i upalnih bolesti |
| KR20200142508A (ko) | 2018-03-08 | 2020-12-22 | 인사이트 코포레이션 | PI3K-γ 저해제로서의 아미노피라진 다이올 화합물 |
| AU2019277560A1 (en) * | 2018-06-01 | 2020-12-10 | Incyte Corporation | Dosing regimen for the treatment of PI3K related disorders |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| CN110833552A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途 |
| LT3847175T (lt) * | 2018-09-05 | 2024-03-25 | Incyte Corporation | Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos |
| EP4251138A1 (de) | 2020-11-30 | 2023-10-04 | Incyte Corporation | Kombinationstherapie mit einem anti-cd19-antikörper und parsaclisib |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| CN112808550B (zh) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | 用于海洋工程的劣化免疫仿生防护界面及制备方法 |
| TW202329976A (zh) | 2021-12-16 | 2023-08-01 | 美商英塞特公司 | Ｐ１３Ｋ—δ抑制劑之局部調配物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| EP1107964B8 (de) | 1998-08-11 | 2010-04-07 | Novartis AG | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AU2002215608B2 (en) | 2000-06-28 | 2004-12-09 | Smithkline Beecham P.L.C. | Wet milling process |
| NZ531378A (en) | 2001-09-19 | 2006-11-30 | Aventis Pharma S | Indolizines as kinase protein inhibitors suitable for treating solid tumours |
| ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| CA2567662C (en) | 2004-06-10 | 2012-11-27 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CN101106983A (zh) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| JP5731978B2 (ja) * | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| EP2845856A1 (de) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidone als PI3K-Hemmer |
| ES2432315T3 (es) | 2009-08-28 | 2013-12-02 | Takeda Pharmaceutical Company Limited | Compuestos de hexahidrooxazinopterina para su uso como inhibidores de mTOR |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ＰＩ３Ｋδ阻害剤としての縮合誘導体 |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| WO2012106343A2 (en) | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| EP3513793B1 (de) | 2011-09-02 | 2021-03-10 | Incyte Holdings Corporation | Heterocyclylamine als pi3k-hemmer |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TW202214254A (zh) * | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| WO2015191677A1 (en) * | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| SI3831833T1 (sl) * | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| AU2019277560A1 (en) * | 2018-06-01 | 2020-12-10 | Incyte Corporation | Dosing regimen for the treatment of PI3K related disorders |
| WO2020102150A1 (en) * | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
-
2014
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-27 TW TW112117019A patent/TWI841376B/zh active
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active IP Right Grant
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 KR KR1020237033761A patent/KR20230145517A/ko active IP Right Grant
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/de active Active
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active IP Right Grant
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/de active Pending
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en active Application Filing
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/de active Active
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active IP Right Grant
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
- 2014-02-28 IL IL311666A patent/IL311666A/en unknown
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920A1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
-
2016
- 2016-06-07 HK HK16106523.5A patent/HK1221398A1/zh unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321B1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-17 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,551 patent/US20220106318A1/en active Pending
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en active Pending
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en active Pending
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495A1/en active Pending
- 2022-12-01 JP JP2022192954A patent/JP2023036609A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283943A (en) | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| HK1221408A1 (zh) | 用於治療成膠質細胞瘤的組合療法 | |
| HK1217706A1 (zh) | 用於治療過度增殖性病症的 -乙酰基氨基- 苯基-雜芳基-氨基羰基或苯基-雜芳基-羰基氨基 苯衍生物 | |
| HUE061618T2 (hu) | Vegyület szemrendellenességek kezelésére | |
| EP3019491A4 (de) | Kinasehemmer zur behandlung von krankheiten | |
| PT3033086T (pt) | Terapia de combinação para o tratamento de cancro | |
| EP2967062A4 (de) | Desethylhydroxychloroquin zur behandlung von erkrankungen in zusammenhang mit entzündungen | |
| HK1221166A1 (zh) | 炎症性病症的治療 | |
| HK1223547A1 (zh) | 癌症治療方法 | |
| ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| EP2970118A4 (de) | Verbindungen zur behandlung neurologischer erkrankungen | |
| AP2015008751A0 (en) | 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases |